Friedreich Ataxia
New Friedreich ataxia research, summarized each month in plain language.
2026 so far: So far in 2026, evidence stayed mixed: reviews of randomized trials showed little average 12-month ataxia-score change, while omaveloxolone was the only drug with consistent mFARS improvement. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Drug evidence summary. Reviews clarified modest average effects; omaveloxolone most consistent.
- Early interventions. More human pilots appeared, but placebo-controlled evidence stayed limited.
- Daily-life impact. Reports increasingly measured function, communication, cognition, and caregiving burden.
- Monitoring advances. More practical biomarkers and staging tools appeared, especially for heart and frataxin.
- Why people differ. Reports linked GAA length and variants to distinct heart and MRI patterns.
New
September 2026
- Heart change stages. Mild thickening often came first; weaker pumping appeared later.
- Early heart scan signs. Some early heart scan findings were linked to later higher risk.
- MRI change patterns. Repeat MRIs showed different change patterns across people.
- Mouse immune-cell swap. Immune-cell replacement helped mice, but is unproven in people.
August 2026
- Mouse gene therapy. In mice, mini-frataxin raised frataxin and improved movement tests.
- Hearing aids. In one case, hearing aids improved quiet speech and fatigue.
- Heart MRI changes. Small studies saw worse MRI trends, but results were uncertain.
July 2026
- Drug study results. Omaveloxolone most consistently improved a standard ataxia score.
- Side effect rates. Side effect rates were reported as similar to controls.
- Clinic access barriers. Travel time and mobility limits affected specialist clinic attendance.
- Early lab findings. Lab and animal studies tested ideas not yet shown in people.
June 2026
- Heart gene therapy. Heart markers changed, but serious side effects were reported.
- Brain stimulation study. Ataxia scores improved, but there was no sham comparison.
- LDL and ApoB. LDL and ApoB increased during omaveloxolone follow-up.
- Cough strength. Weaker cough was linked to weaker breathing muscles.
May 2026
- 12-month trial scores. Across randomized drug trials, overall ataxia scores changed little on average after 12 months.
- Frataxin replacement in animals. In animal studies, broader frataxin replacement approaches improved movement, but these results do not directly predict effects in people.
- Hearing and vision signal tests. In one study, hearing and vision signal timing tests were often abnormal and closely tracked symptom severity.
- Blood microRNA heart signal. A small blood microRNA panel separated people with thickened-heart disease in a small study.
April 2026
- Home exercise and fitness. In a small trial, a structured home exercise program improved a lab-based fitness test over the short term.
- Nicotinamide riboside effect. In the same trial, it remained unclear whether nicotinamide riboside added benefit beyond exercise.
- Frataxin in easier samples. Research studies measured frataxin in skin, cheek cells, and blood-based samples to track levels without relying on hard-to-access tissues.
- Predicting progression. In one follow-up study, GAA1 repeat length and starting severity predicted change better than a single spinal-fluid nerve-injury marker.
March 2026
- MRI changes and symptoms. In some studies, MRI changes tracked with symptom measures.
- MRI-based groups. Some reports grouped people into MRI-based subtypes and stages.
- Gene activity signals. Gene activity studies found repeated cell signals, but not a routine clinical test.
February 2026
- Heart mitochondria changes. In a mouse study, heart cells showed iron buildup inside mitochondria, lower energy production, and signs that removal of damaged mitochondria was disrupted.
- Iron differs by organ. In a partial frataxin mouse model, iron-related changes looked different in the cerebellum, heart, and liver, suggesting one test may not reflect all organs equally.
- Care shaped by frailty. A case report described esophageal cancer in a person with severe Friedreich ataxia-related heart disease and frailty, where care focused on symptom relief when curative treatment was not pursued.
January 2026
- Brain circuit tracking measures. A movement-related brain circuit showed differences in structure, connectivity, and energy-related signals in Friedreich ataxia, and some measures were linked to symptom severity as potential research tracking tools.
- Daily functioning and caregiving needs. Greater disability was associated with more difficulty in daily activities and communication, lower quality of life, and higher informal caregiving needs and costs.
- Cell stress signals in the lab. In patient-derived cells, adding specific compounds improved laboratory markers of oxidative stress, lipid damage, and energy production, but these findings have not been tested as benefits in people.
Get the monthly update by email
Subscribe here to receive an email when a new monthly Friedreich ataxia update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).